Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Surrogate end points in heart failure.

Inder S Anand1, Viorel G Florea, Lloyd Fisher

  • 1University of Minnesota Medical School and Veterans Affairs Medical Center, Minneapolis, Minnesota, USA. anand001@tc.umn.edu

Journal of the American College of Cardiology
|May 3, 2002
PubMed
Summary

Evaluating treatments for heart failure (HF) requires careful endpoint selection. Currently, no well-established surrogate endpoints reliably predict treatment success in chronic heart failure patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance of the HFpEF-ABA, H<sub>2</sub>FPEF, and HFA-PEFF Algorithms in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.

Journal of cardiac failure·2026
Same author

Heart rate and atrial fibrillation/flutter in HFmrEF/HFpEF: a participant-level analysis across five randomized clinical trials.

European journal of heart failure·2026
Same author

Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Journal of the American College of Cardiology·2025
Same author

Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.

Journal of the American College of Cardiology·2025
Same author

Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF.

European heart journal. Cardiovascular pharmacotherapy·2025
Same author

Impact of lifting school mask mandates on community SARS-CoV-2 cases, hospitalizations, and deaths: a retrospective observational study.

Frontiers in public health·2025

Area of Science:

  • Cardiology
  • Clinical Pharmacology
  • Biostatistics

Background:

  • Increasing pharmacologic options for heart failure (HF) necessitate reassessment of therapeutic efficacy evaluation.
  • Surrogate endpoints offer potential for reduced trial duration and sample size, impacting cost and feasibility.
  • Understanding drug mechanisms of action is enhanced by surrogate endpoint analysis, aiding clinical management.

Purpose of the Study:

  • To analyze the potential utility of surrogate endpoints in clinical trials for chronic heart failure (HF).
  • To discuss the broader applications of surrogate endpoints in medical research.
  • To highlight the limitations and challenges in identifying validated surrogate endpoints for HF.

Main Methods:

  • Literature review and analysis of existing clinical trial methodologies in heart failure.

Related Experiment Videos

  • Definition and comparison of true endpoints (e.g., mortality) versus surrogate endpoints (e.g., ejection fraction).
  • Discussion of the theoretical benefits and practical challenges of implementing surrogate endpoints.

    • Main Results:

    • Surrogate endpoints, such as ejection fraction or left ventricular volume, are biologically closer to the disease process in HF.
    • Potential benefits include reduced sample size, shorter trial duration, and cost savings.
    • Surrogate endpoints can provide insights into drug mechanisms of action.

    Conclusions:

    • No well-established surrogate endpoint currently exists for reliably evaluating treatments in chronic heart failure (HF).
    • Further research is needed to identify and validate suitable surrogate endpoints.
    • Careful consideration of limitations is crucial when using surrogate endpoints in clinical research.